SCHEMBL26927340

SCHEMBL26927340

Cc1cc(CO[Si](C)(C)C(C)(C)C)n[nH]1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR84 Q9NQS5 1/20 0.33
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ DAO P14920 1/20 0.32
▸ HCAR2 Q8TDS4 1/20 0.32
▸ PDE10A Q9Y233 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ DUT P33316 2/20 0.31
▸ CYP2C9 P11712 2/20 0.30
▸ CYP2C19 P33261 2/20 0.30
▸ ALPL P05186 2/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ CYP19A1 P11511 1/20 0.30
▸ PDE1B Q01064 1/20 0.30
▸ HTR1A P08908 1/20 0.30
▸ ADRA2A P08913 1/20 0.30
▸ CHRM1 P11229 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24624979 0.86 HCAR2 (0.34) HCAR2DUT
SCHEMBL31284378 0.81 DUT (0.30) DUT
SCHEMBL26140216 0.78 KDM5A (0.30) —
SCHEMBL23277749 0.78 GPR84 (0.35) GPR84NPC1RAB9ADAOHCAR2
SCHEMBL25934682 0.77 HCAR2 (0.34) HCAR2
SCHEMBL25934687 0.77 HCAR2 (0.31) HCAR2
SCHEMBL19045238 0.75 — —
SCHEMBL13936715 0.75 ITK (0.43) —
SCHEMBL25690640 0.73 DUT (0.36) DUTCYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL12126142 0.73 CYP2C9 (0.37) GPR84NPC1RAB9ADAOHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353864-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2025-11-20 — — US disclosed
EP-4536224-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE Blossomhill Therapeutics, Inc. (US) 2025-04-16 — — EP disclosed
CN-119421709-A Indazole-containing macrocyclic compounds and uses thereof 荣山医药股份有限公司 2025-02-11 — — CN disclosed
WO-2023240138-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
WO-2023240138-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353864-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE AADAC, PAICS, CYP3A43 GPR84 3997/4885NPC1 55/4885RAB9A 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback